Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Tong-Zhang Xian"'
Publikováno v:
Cardiovascular Diabetology, Vol 19, Iss 1, Pp 1-9 (2020)
Abstract Background Exenatide, a glucagon like peptide 1 analog, has been suggested to reduce the cardiovascular disease risk factors, such as body weight, blood pressure and subclinical atherosclerosis in patients with type 2 diabetes mellitus (T2DM
Externí odkaz:
https://doaj.org/article/e2714445940143199ff5cb9a77b96f04
Autor:
Jie Zhang, Tong-Zhang Xian, Yu Teng, Xiuzhi Wang, Ming-Xiao Wu, Chen Li, Weihao Wang, Fuli Man, Xianbo Zhang, Xiaoxia Wang, Li-Xin Guo
Publikováno v:
International Journal of Clinical Practice, Vol 2022 (2022)
Background. Exenatide is a glucagon-like peptide-1 receptor agonist that can reduce body weight. This study aimed to determine the efficacy of exenatide on body mass index (BMI) reduction in patients with type 2 diabetes mellitus (T2DM) with differin
Externí odkaz:
https://doaj.org/article/c810bfec4cbc45feb30a8a32032ebbd7
Autor:
Jie Zhang, Tong-Zhang Xian, Ming-Xiao Wu, Chen Li, Weihao Wang, Fuli Man, Xianbo Zhang, Xiaoxia Wang, Qi Pan, Lixin Guo, Zhang, Jie, Xian, Tong-Zhang, Wu, Ming-Xiao, Li, Chen, Wang, Weihao, Man, Fuli, Zhang, Xianbo, Wang, Xiaoxia, Pan, Qi, Guo, Lixin
Publikováno v:
Journal of Investigative Medicine (Sage Publications Inc.); Oct2022, Vol. 70 Issue 7, p1529-1535, 7p
Additional file 1: Table S1. Titration protocol for insulin in patients with type 2 diabetes mellitus.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::547592e192cebd21494b005a4a356c8b
